University of Miami Hospital and Clinics

University of Miami Hospital and Clinics was paid $62.12M by Medicaid between Jan 2018 and Dec 2024, across 648 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 6.9% of everything it billed.

33Billing provider infoUNIVERSITY OF MIAMI HOSPITAL AND CLINICS
MIAMI, FL 33136

33aNPI1679660617assigned 10/10/2006

33bProvider typeParenteral & Enteral Nutrition Supplies (DME)

28Total paid$62.12M

24GClaims2,357,529

24DCodes billed648

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Parenteral & Enteral Nutrition Supplies (DME) providers in Florida

Rank by total paid#2 of 53

Median peer was paid$462K

This provider vs. median134×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	221,805	$6.33M
2019	482,107	$13.13M
2020	437,912	$8.61M
2021	517,536	$13.03M
2022	489,609	$15.04M
2023	150,596	$4.88M
2024incomplete	57,964	$1.09M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0463	Hospital outpatient clinic visit for assessment and management of a patient	6.9%	201,954	136,324	$4.31M
J9271	Injection, pembrolizumab, 1 mg	5.6%	3,152	1,981	$3.46M
80053	Comprehensive metabolic panel	3.5%	123,454	71,809	$2.19M
77386		3.4%	12,142	1,078	$2.09M
99282	Emergency department visit for the evaluation and management, low to moderate severity	3.3%	35,893	30,972	$2.06M
67028	Intravitreal injection of a pharmacologic agent	2.7%	16,135	11,901	$1.69M
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	2.3%	33,758	7,584	$1.41M
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	2.1%	39,892	19,296	$1.32M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	1.8%	33,565	16,726	$1.14M
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	1.7%	1,188	636	$1.03M
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	1.6%	19,561	11,064	$995K
77336		1.6%	5,678	2,242	$976K

636 more codes

J9299	Injection, nivolumab, 1 mg	1.3%	2,607	$821K
99285	Emergency room visit (most serious)	1.3%	15,323	$818K
36415	Collection of venous blood by venipuncture	1.3%	75,472	$811K
J2505	Injection, pegfilgrastim, 6 mg	1.2%	2,925	$751K
J7030	Infusion, normal saline solution , 1000 cc	1.2%	19,883	$744K
78815	Positron emission tomography (PET) for limited area imaging	1.2%	6,237	$719K
77412		1.2%	4,686	$719K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	1.1%	6,263	$662K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.0%	141,566	$645K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	1.0%	6,772	$637K
J7050	Infusion, normal saline solution, 250 cc	1.0%	27,632	$628K
J9035	Injection, bevacizumab, 10 mg	<1%	3,292	$605K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	17,704	$598K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	<1%	1,880	$591K
G0378	Hospital observation service, per hour	<1%	13,563	$574K
99284	Emergency room visit (serious)	<1%	11,368	$570K
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis	<1%	4,077	$568K
A9577	Injection, gadobenate dimeglumine (multihance), per ml	<1%	10,060	$541K
J9306	Injection, pertuzumab, 1 mg	<1%	522	$526K
96361	Intravenous infusion, hydration; each additional hour	<1%	11,311	$501K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	11,945	$494K
J1453	Injection, fosaprepitant, 1 mg	<1%	8,166	$488K
J0178	Injection, aflibercept, 1 mg	<1%	6,021	$474K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	5,934	$474K
74177	Computed tomography, abdomen and pelvis; with contrast material	<1%	8,942	$473K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	12,625	$434K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	<1%	1,111	$418K
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	<1%	2,298	$406K
96402		<1%	3,907	$403K
C9257	Injection, bevacizumab, 0.25 mg	<1%	6,851	$399K
99283	Emergency room visit (moderate)	<1%	8,416	$371K
J9312	Injection, rituximab, 10 mg	<1%	1,028	$365K
96375	Therapeutic injection; each additional sequential IV push	<1%	33,870	$361K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	3,846	$335K
31237		<1%	459	$331K
92134		<1%	34,729	$320K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	22,689	$312K
77300		<1%	1,902	$312K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	3,216	$305K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	2,145	$296K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	5,732	$296K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	<1%	704	$280K
49083		<1%	1,190	$268K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	6,432	$260K
70450	Computed tomography, head or brain; without contrast material	<1%	3,636	$250K
31575		<1%	3,234	$241K
J0897	Injection, denosumab, 1 mg	<1%	3,035	$240K
80048	Basic metabolic panel (calcium, ionized)	<1%	22,491	$225K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	2,243	$220K
77385		<1%	1,025	$219K
76536		<1%	4,123	$215K
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	687	$214K
92557		<1%	4,215	$214K
P9035	Platelets, pheresis, leukocytes reduced, each unit	<1%	1,006	$213K
36430		<1%	4,776	$207K
96367		<1%	9,688	$205K
99213	Doctor's office visit, returning patient (routine)	<1%	2,053	$195K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	<1%	504	$191K
31579		<1%	890	$188K
Q5101	Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram	<1%	2,709	$187K
77338		<1%	1,159	$184K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	2,785	$182K
92083		<1%	11,062	$181K
J0585	Injection, onabotulinumtoxina, 1 unit	<1%	1,582	$178K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	971	$172K
83735		<1%	24,918	$171K
92250		<1%	11,397	$171K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	3,272	$165K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	10,248	$159K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	7,501	$154K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	947	$154K
96417		<1%	8,676	$150K
92567		<1%	7,242	$146K
76770		<1%	2,941	$146K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	18,049	$145K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	24,317	$143K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	1,439	$143K
95811		<1%	541	$143K
76512		<1%	2,180	$142K
36561		<1%	225	$141K
96415		<1%	5,475	$139K
96523		<1%	11,275	$135K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	8,218	$135K
J9202	Goserelin acetate implant, per 3.6 mg	<1%	1,337	$129K
J7060	5% dextrose/water (500 ml = 1 unit)	<1%	11,129	$128K
96401		<1%	4,552	$121K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	20,399	$119K
71046	Radiologic examination, chest; 2 views	<1%	6,708	$118K
31231		<1%	1,400	$118K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	1,732	$118K
10005		<1%	770	$114K
70543		<1%	1,514	$112K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	3,049	$111K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	2,010	$111K
J3380	Injection, vedolizumab, intravenous, 1 mg	<1%	52	$110K
96416		<1%	3,357	$108K
71250		<1%	4,173	$108K
V2632	Posterior chamber intraocular lens	<1%	4,473	$104K
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	<1%	4,494	$102K
97161		<1%	3,845	$97K
67228		<1%	301	$97K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	1,472	$96K
77066	Tomosynthesis, mammo	<1%	3,003	$93K
92018		<1%	656	$93K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	1,682	$92K
66982		<1%	518	$91K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	23,216	$89K
74183		<1%	1,328	$87K
87070		<1%	4,825	$86K
J9263	Injection, oxaliplatin, 0.5 mg	<1%	2,481	$84K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	4,101	$83K
76641		<1%	1,345	$83K
72197		<1%	1,198	$81K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	2,113	$81K
83615		<1%	18,848	$80K
20610		<1%	1,871	$80K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	<1%	59	$79K
92626		<1%	538	$77K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	903	$74K
77334		<1%	1,186	$74K
77301		<1%	1,106	$73K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	1,661	$71K
86850		<1%	12,695	$71K
71275	Computed tomographic angiography, chest, with contrast material	<1%	699	$69K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	3,786	$69K
82378		<1%	12,993	$69K
J9045	Injection, carboplatin, 50 mg	<1%	2,571	$67K
77080		<1%	2,551	$67K
88304		<1%	2,122	$67K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	967	$66K
J9395	Injection, fulvestrant, 25 mg	<1%	1,393	$65K
81003		<1%	9,518	$64K
J0475	Injection, baclofen, 10 mg	<1%	247	$64K
88185		<1%	2,187	$64K
92588		<1%	973	$63K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	624	$63K
72141		<1%	1,098	$61K
20611		<1%	716	$61K
70491		<1%	1,234	$59K
76513		<1%	913	$58K
92235		<1%	1,669	$58K
76642		<1%	1,749	$57K
78306		<1%	897	$57K
J9190	Injection, fluorouracil, 500 mg	<1%	5,789	$56K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	219	$56K
92133		<1%	6,895	$56K
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	<1%	76	$56K
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	2,057	$55K
84443	Thyroid stimulating hormone (TSH)	<1%	18,591	$55K
85610		<1%	20,710	$55K
93970		<1%	1,897	$54K
87015		<1%	2,683	$54K
72110		<1%	1,610	$52K
J9022	Injection, atezolizumab, 10 mg	<1%	19	$51K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	<1%	2,824	$51K
84550		<1%	3,787	$49K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	903	$47K
82728		<1%	11,985	$47K
71045	Radiologic examination, chest; single view	<1%	11,109	$45K
77065	Tomosynthesis, mammo	<1%	1,750	$45K
86900		<1%	14,839	$44K
76830	Ultrasound, transvaginal	<1%	1,126	$44K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	10,201	$44K
42820	Tonsillectomy and adenoidectomy; younger than age 12	<1%	15	$43K
77012		<1%	275	$43K
92550		<1%	674	$43K
C1769	Guide wire	<1%	3,647	$42K
31615		<1%	91	$41K
70544		<1%	551	$41K
81002		<1%	3,445	$41K
85027		<1%	12,937	$41K
92060		<1%	1,188	$41K
J1644	Injection, heparin sodium, per 1000 units	<1%	7,892	$40K
J9267	Injection, paclitaxel, 1 mg	<1%	3,207	$39K
A9579	Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml	<1%	1,066	$39K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	9,332	$39K
73030		<1%	1,754	$39K
81025		<1%	1,038	$38K
J7120	Ringers lactate infusion, up to 1000 cc	<1%	12,136	$38K
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	2,340	$38K
86901		<1%	14,664	$38K
38222		<1%	188	$37K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	2,322	$37K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	<1%	21	$36K
73564		<1%	1,231	$36K
J1442	Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	<1%	304	$36K
93017		<1%	1,575	$35K
88342		<1%	2,642	$35K
96411		<1%	3,958	$35K
94010		<1%	1,270	$35K
97162		<1%	710	$35K
66821		<1%	459	$35K
81001		<1%	14,369	$34K
96377		<1%	2,415	$34K
86301		<1%	3,588	$34K
J9171	Injection, docetaxel, 1 mg	<1%	1,618	$34K
85730		<1%	14,718	$34K
62370		<1%	283	$33K
99214	Doctor's office visit, returning patient (more involved)	<1%	459	$33K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	2,892	$33K
J9145	Injection, daratumumab, 10 mg	<1%	623	$33K
J9041	Injection, bortezomib, 0.1 mg	<1%	281	$31K
97535	Self-care/home management training, each 15 minutes	<1%	1,490	$31K
87086	Culture, bacterial; quantitative colony count, urine	<1%	8,981	$31K
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	2,307	$31K
77290		<1%	222	$30K
J2777	Injection, faricimab-svoa, 0.1 mg	<1%	123	$30K
78816		<1%	255	$30K
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	38,015	$29K
76514		<1%	856	$29K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	307	$29K
88341		<1%	1,437	$28K
74178		<1%	883	$28K
67113		<1%	73	$28K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	<1%	418	$28K
87040		<1%	5,594	$27K
86300		<1%	7,916	$27K
51798		<1%	1,637	$27K
77063	Screening digital breast tomosynthesis, bilateral	<1%	2,805	$26K
J0485	Injection, belatacept, 1 mg	<1%	1,904	$26K
J9070	Cyclophosphamide, 100 mg	<1%	912	$26K
36592		<1%	2,401	$26K
84439		<1%	8,299	$26K
73130		<1%	854	$25K
84100		<1%	12,051	$25K
73630		<1%	1,596	$25K
84484		<1%	9,823	$25K
J0640	Injection, leucovorin calcium, per 50 mg	<1%	3,692	$25K
77001		<1%	1,919	$25K
92025		<1%	1,376	$25K
69210		<1%	481	$24K
94726		<1%	1,089	$24K
72100		<1%	1,154	$24K
85007		<1%	7,894	$23K
Q9956	Injection, octafluoropropane microspheres, per ml	<1%	1,247	$23K
99201		<1%	255	$23K
70486		<1%	436	$23K
73610		<1%	745	$22K
52000		<1%	89	$22K
94060		<1%	682	$22K
92587		<1%	961	$22K
96368		<1%	2,722	$22K
92582		<1%	585	$22K
87077		<1%	5,175	$22K
97116		<1%	611	$22K
J2997	Injection, alteplase recombinant, 1 mg	<1%	1,726	$22K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	1,471	$21K
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	<1%	203	$21K
70480		<1%	368	$21K
82784		<1%	12,808	$21K
82248		<1%	9,547	$21K
J1756	Injection, iron sucrose, 1 mg	<1%	2,599	$21K
J0690	Injection, cefazolin sodium, 500 mg	<1%	7,001	$21K
86923		<1%	4,260	$20K
64612		<1%	193	$20K
69436	Tympanostomy (requiring insertion of ventilating tube), general anesthesia	<1%	62	$20K
93971		<1%	1,055	$20K
87075		<1%	2,862	$20K
77295		<1%	63	$19K
92285		<1%	2,603	$19K
J9305	Injection, pemetrexed, not otherwise specified, 10 mg	<1%	135	$19K
77373		<1%	84	$18K
96409		<1%	1,673	$18K
83540		<1%	8,064	$18K
J3480	Injection, potassium chloride, per 2 meq	<1%	1,457	$18K
83550		<1%	7,843	$18K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	6,320	$18K
Q0163	Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen	<1%	5,234	$18K
72050		<1%	520	$17K
77280		<1%	86	$17K
84156		<1%	1,813	$17K
66180		<1%	15	$17K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	478	$17K
72158		<1%	402	$17K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	2,263	$17K
82607		<1%	4,493	$17K
J1170	Injection, hydromorphone, up to 4 mg	<1%	7,239	$16K
73502		<1%	922	$16K
83880		<1%	3,635	$16K
73110		<1%	405	$15K
19083		<1%	31	$15K
76882		<1%	188	$15K
92604		<1%	842	$15K
84481		<1%	2,235	$14K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	44	$14K
72157		<1%	147	$14K
88313		<1%	1,489	$14K
86304		<1%	1,854	$14K
72156		<1%	208	$14K
92136		<1%	1,269	$14K
88360		<1%	817	$14K
J1815	Injection, insulin, per 5 units	<1%	4,671	$13K
74160		<1%	308	$13K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	12,604	$13K
85651		<1%	3,691	$13K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	3,261	$13K
73221		<1%	119	$13K
88112		<1%	650	$13K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	216	$13K
92020		<1%	1,704	$12K
88307		<1%	897	$12K
82550		<1%	7,419	$12K
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	2,217	$12K
80061	Lipid panel	<1%	7,559	$12K
82746		<1%	3,169	$12K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	1,138	$11K
87186		<1%	5,223	$11K
72131		<1%	571	$11K
92524		<1%	575	$11K
84153		<1%	4,259	$11K
81050		<1%	1,227	$11K
67036		<1%	49	$11K
82570		<1%	1,239	$10K
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	620	$10K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	4,036	$10K
J9206	Injection, irinotecan, 20 mg	<1%	2,678	$10K
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	<1%	385	$10K
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	2,419	$10K
87206		<1%	2,085	$10K
76937		<1%	1,585	$9K
88321		<1%	467	$9K
76942		<1%	503	$9K
83036	Hemoglobin; glycosylated (A1C)	<1%	7,529	$9K
82553		<1%	6,047	$9K
J2060	Injection, lorazepam, 2 mg	<1%	1,348	$9K
G0260	Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography	<1%	91	$9K
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	637	$9K
86140		<1%	4,178	$9K
J9310	Injection, rituximab, 100 mg	<1%	41	$9K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	992	$9K
87340		<1%	1,900	$9K
73560		<1%	712	$9K
64483		<1%	114	$9K
72082		<1%	299	$8K
73562		<1%	657	$8K
83970		<1%	1,272	$8K
92579		<1%	1,218	$8K
83690		<1%	8,289	$8K
72125	Computed tomography, cervical spine; without contrast material	<1%	378	$8K
70496		<1%	67	$8K
85045		<1%	11,555	$8K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	8,392	$8K
83883		<1%	3,268	$8K
82375		<1%	770	$8K
82105		<1%	1,688	$8K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	1,243	$7K
84155		<1%	4,448	$7K
88300		<1%	555	$7K
73521		<1%	285	$7K
87205		<1%	3,283	$7K
J3489	Injection, zoledronic acid, 1 mg	<1%	1,704	$7K
84132		<1%	560	$7K
84165		<1%	4,515	$7K
76881		<1%	144	$7K
84480		<1%	990	$7K
77332		<1%	204	$7K
93975		<1%	379	$7K
72040		<1%	177	$7K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	123	$6K
87799		<1%	3,830	$6K
86334		<1%	3,843	$6K
84702		<1%	1,441	$6K
P9047	Infusion, albumin (human), 25%, 50 ml	<1%	1,053	$6K
86803		<1%	2,203	$6K
84436		<1%	1,593	$6K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	5,775	$6K
C9097	Inj, faricimab-svoa, 0.1 mg	<1%	34	$6K
77072		<1%	114	$6K
94664		<1%	2,469	$6K
87497		<1%	4,442	$6K
97165		<1%	1,545	$6K
74150		<1%	44	$6K
G8984	Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	275	$6K
86704		<1%	1,211	$5K
92556		<1%	117	$5K
83605		<1%	3,834	$5K
83020		<1%	2,193	$5K
74018		<1%	361	$5K
29581		<1%	365	$5K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	2,515	$5K
J2778	Injection, ranibizumab, 0.1 mg	<1%	42	$5K
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	1,565	$5K
Q3014	Telehealth originating site facility fee	<1%	17,602	$5K
84703		<1%	2,018	$5K
C1788	Port, indwelling (implantable)	<1%	216	$5K
88184		<1%	1,878	$4K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	3,079	$4K
G8985	Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	275	$4K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	294	$4K
92586		<1%	91	$4K
82150		<1%	3,338	$4K
88172		<1%	667	$4K
76377		<1%	373	$4K
94729		<1%	2,017	$4K
V2785	Processing, preserving and transporting corneal tissue	<1%	82	$4K
70482		<1%	13	$4K
0399T		<1%	43	$4K
74240		<1%	70	$4K
87449		<1%	3,266	$4K
80076		<1%	3,822	$4K
C8908	Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral	<1%	33	$4K
83516		<1%	746	$4K
64642		<1%	29	$3K
93320		<1%	110	$3K
99215	Doctor's office visit, returning patient (complex)	<1%	71	$3K
87102		<1%	878	$3K
92132		<1%	435	$3K
93225		<1%	336	$3K
36593		<1%	228	$3K
96376		<1%	1,745	$3K
74230		<1%	69	$3K
G0268	Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing	<1%	152	$3K
88108		<1%	833	$3K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	4,650	$3K
C1887	Catheter, guiding (may include infusion/perfusion capability)	<1%	295	$3K
94618		<1%	370	$3K
76870		<1%	33	$3K
84403		<1%	1,230	$3K
J0461	Injection, atropine sulfate, 0.01 mg	<1%	1,113	$3K
65222		<1%	70	$3K
64643		<1%	26	$2K
J9000	Injection, doxorubicin hydrochloride, 10 mg	<1%	523	$2K
80197		<1%	1,390	$2K
83625		<1%	133	$2K
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	<1%	673	$2K
36410		<1%	214	$2K
82043		<1%	1,927	$2K
87081		<1%	2,008	$2K
93880		<1%	125	$2K
92520		<1%	181	$2K
74220		<1%	77	$2K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	297	$2K
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	1,274	$2K
J3370	Injection, vancomycin hcl, 500 mg	<1%	1,218	$2K
93226		<1%	245	$2K
C1729	Catheter, drainage	<1%	315	$2K
88311		<1%	588	$2K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	1,029	$2K
86902		<1%	538	$2K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	<1%	642	$2K
P9021	Red blood cells, each unit	<1%	72	$2K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	2,366	$2K
94660		<1%	31	$2K
86706		<1%	1,131	$2K
82803		<1%	776	$2K
43235		<1%	35	$2K
88312		<1%	14	$1K
80198		<1%	73	$1K
92652		<1%	45	$1K
17311		<1%	37	$1K
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	125	$1K
92240		<1%	31	$1K
87533		<1%	1,568	$1K
83050		<1%	772	$1K
94727		<1%	486	$1K
J1940	Injection, furosemide, up to 20 mg	<1%	1,109	$1K
86769		<1%	26	$1K
82945		<1%	180	$1K
87507		<1%	46	$1K
10060		<1%	14	$1K
72114		<1%	14	$1K
76000		<1%	636	$1K
36600		<1%	414	$1K
82533		<1%	1,293	$1K
86328		<1%	54	$1K
99203	Doctor's office visit, new patient (routine)	<1%	13	$1K
15770		<1%	28	$1K
72070		<1%	65	$1K
82977		<1%	2,811	$1K
J7070	Infusion, d5w, 1000 cc	<1%	131	$1K
86038		<1%	487	$1K
93356		<1%	1,385	$1K
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	<1%	208	$1K
93325		<1%	140	$1K
82610		<1%	1,852	$1K
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	<1%	540	$1K
73120		<1%	59	$1K
85384		<1%	276	$1K
92597		<1%	68	$1K
76516		<1%	37	$974.83
77470		<1%	14	$953.13
82024		<1%	1,135	$880.22
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	1,084	$824.22
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	15	$797.52
64493		<1%	32	$772.04
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	410	$744.88
93296		<1%	48	$736.52
92526		<1%	16	$677.02
86703		<1%	147	$667.69
G8981	Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	43	$635.43
92082		<1%	119	$609.72
83021		<1%	115	$593.35
72202		<1%	41	$593.18
85240		<1%	120	$582.02
72146		<1%	32	$581.78
86592		<1%	386	$562.78
93350		<1%	19	$552.19
73620		<1%	15	$543.28
C1751	Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	<1%	365	$523.85
86922		<1%	160	$523.44
L8509	Tracheo-esophageal voice prosthesis, inserted by a licensed health care provider, any type	<1%	14	$516.01
92602		<1%	14	$505.30
93246		<1%	29	$502.95
83521		<1%	1,930	$502.71
92650		<1%	32	$500.01
95874		<1%	291	$497.20
80069		<1%	309	$485.44
P3000	Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision	<1%	56	$476.07
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	4,078	$472.37
20553		<1%	65	$462.02
36590		<1%	16	$461.56
82232		<1%	451	$454.39
80377		<1%	28	$437.96
64447		<1%	15	$420.43
83001		<1%	51	$391.08
10022		<1%	20	$384.09
80320		<1%	132	$382.36
20605		<1%	21	$380.73
C1758	Catheter, ureteral	<1%	42	$361.80
82670		<1%	59	$348.05
86708		<1%	121	$345.14
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	<1%	82	$341.75
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	53	$341.71
75572		<1%	14	$340.16
86403		<1%	21	$333.11
70498		<1%	15	$332.48
G8982	Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	43	$322.99
85230		<1%	13	$314.56
C1726	Catheter, balloon dilatation, non-vascular	<1%	47	$309.24
86606		<1%	200	$301.87
87516		<1%	89	$294.55
81015		<1%	263	$281.87
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	66	$272.54
89051		<1%	119	$266.52
87305		<1%	391	$256.94
86235		<1%	74	$255.65
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	<1%	17	$245.96
J2785	Injection, regadenoson, 0.1 mg	<1%	474	$236.61
86880		<1%	119	$235.88
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	395	$220.54
85014		<1%	260	$216.43
82664		<1%	13	$203.97
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	57	$198.12
83520		<1%	36	$191.02
87116		<1%	399	$187.17
85378		<1%	669	$175.18
77003		<1%	14	$169.40
86480		<1%	138	$166.77
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	69	$165.39
90715		<1%	307	$165.05
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	17	$157.05
84311		<1%	182	$138.18
86357		<1%	14	$134.81
86255		<1%	27	$123.92
G8997	Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	66	$114.33
G8996	Swallowing functional limitation, current status at therapy episode outset and at reporting intervals	<1%	65	$114.33
80074		<1%	129	$113.85
C2617	Stent, non-coronary, temporary, without delivery system	<1%	39	$109.56
86431		<1%	82	$106.82
Q0247	Injection, sotrovimab, 500 mg	<1%	20	$104.48
J7325	Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg	<1%	18	$102.44
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	86	$100.44
36591		<1%	44	$95.97
J2360	Injection, orphenadrine citrate, up to 60 mg	<1%	779	$94.25
A9541	Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	<1%	14	$94.02
86225		<1%	39	$89.92
G8987	Self care functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	17	$86.05
G8988	Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	17	$86.05
92226		<1%	15	$73.62
82330		<1%	178	$70.86
89050		<1%	31	$67.67
83986		<1%	95	$55.11
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	319	$51.43
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	882	$47.93
99153	Mod sedat endo service >5yrs	<1%	44	$45.83
83002		<1%	50	$42.05
86777		<1%	18	$38.50
84402		<1%	30	$37.87
84146		<1%	30	$24.30
84154		<1%	220	$24.11
86355		<1%	15	$23.28
86360		<1%	13	$23.28
86359		<1%	15	$23.28
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	315	$22.43
87535		<1%	17	$22.06
77387		<1%	266	$19.68
99152		<1%	31	$19.35
83010		<1%	47	$17.58
84145		<1%	151	$17.17
G8998	Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting	<1%	26	$15.63
82530		<1%	222	$6.75
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	25	$4.79
85660		<1%	18	$3.96
84479		<1%	16	$3.84
77002		<1%	17	$0.51
87556		0%	18	$0.00
86870		0%	57	$0.00
G0008	Administration of influenza virus vaccine	0%	61	$0.00
J1741	Injection, ibuprofen, 100 mg	0%	245	$0.00
97802		0%	103	$0.00
92700		0%	48	$0.00
90935	Hemodialysis procedure with single evaluation by a physician	0%	112	$0.00
85018		0%	16	$0.00
90686		0%	15	$0.00
J7042	5% dextrose/normal saline (500 ml = 1 unit)	0%	48	$0.00
94200		0%	16	$0.00
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	0%	57	$0.00
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	0%	13	$0.00
64494		0%	16	$0.00
88377		0%	22	$0.00
10006		0%	14	$0.00
86945		0%	17	$0.00
73720		0%	17	$0.00
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	0%	13	$0.00
J2003	Injection, lidocaine hydrochloride, 1 mg	0%	15	$0.00
J9370	Vincristine sulfate, 1 mg	0%	306	$0.00
90682		0%	28	$0.00
88237		0%	18	$0.00
J1956	Injection, levofloxacin, 250 mg	0%	146	$0.00
99499		0%	140	$0.00
J9260	Injection, methotrexate sodium, 50 mg	0%	114	$0.00
88365		0%	31	$0.00
J0692	Injection, cefepime hydrochloride, 500 mg	0%	313	$0.00
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	0%	12	$0.00
J9060	Injection, cisplatin, powder or solution, 10 mg	0%	47	$0.00
J2550	Injection, promethazine hcl, up to 50 mg	0%	115	$0.00
86787		0%	17	$0.00
92585		0%	12	$0.00
J1738	Injection, meloxicam, 1 mg	0%	13	$0.00
J0137	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	0%	13	$0.00
87101		0%	13	$0.00
J1171	Injection, hydromorphone, 0.1 mg	0%	33	$0.00
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	0%	13	$0.00
01999		0%	26	$0.00
J1596	Injection, glycopyrrolate, 0.1 mg	0%	13	$0.00
82652		0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialJORDAN, MONICA (AVP OF GVT REPORTING AND REIMB)

Same official

Other billing entities under JORDAN, MONICA

Full network →

Provider	Location	Paid
Mobile Infirmary Association	Mobile, AL	$4.59M
Gulf Health Hospitals, INC.	Fairhope, AL	$7K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.